mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antidepressant Action of Ketamine: In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959 ; see the Perspective by Cryan and O'Leary ) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have suggested that ketamine can increase the synthesis of synaptic proteins through BDNF signaling dependent on the activate protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) signaling cascades. 378 , 379”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone can also alleviate neural dysfunction linked to symptoms of depression by boosting the synapse and spine density and restoring spinogenesis, in addition to correcting depressive-like behaviors in animal models of depression. 378 , 477”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine rapidly and transiently increases glutamate transmission in the PFC, possibly via inhibition of tonically active GABAergic inter-neurons, and the resulting burst of glutamate is thought to underlie ketamine induction of synapto-genesis (6, 7).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine increases BDNF release and stimulates mTORC1 signaling, which leads to increased levels of synaptic proteins (i.e., GluR1, PSD95, and synapsin 1) and increased number and function of synapses in the PFC 4,22,35 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Functional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Self-citation
Cited by
Items 901–1,000 of 1,062
Lauterbach, E. C. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.02.012 · Cited by 54
“also affect AMPA receptor trafficking [47,48].”
BackgroundInfluentialZhang, G.-F., Wang, J., Han, J., Guo, J., Xie, Z.-M., Pan, W., Yang, J., & Sun, K. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.08.006 · Cited by 54
Hou, X.-Y., Hu, Z., Zhang, D.-Z., Lu, W., Zhou, J., Wu, P.-F., Guan, X., Han, Q.-Q., Deng, S., Zhang, H., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6737 · Cited by 54
“The immobility time was counted offline by a stopwatch in seconds in a single-blind study (25).”
InfluentialInhibition of a Descending Prefrontal Circuit Prevents Ketamine-Induced Stress Resilience in Females
Dolzani, S. D., Baratta, M. V., Moss, J. M., Leslie, N. L., Tilden, S. G., Sørensen, A. T., Watkins, L. R., Lin, Y., & Maier, S. F. (2018) · eneuro · doi:10.1523/eneuro.0025-18.2018 · Cited by 50
“Plastic changes in the prelimbic region (PL) of the medial prefrontal cortex (mPFC), a potent regulator of DRN activity (for review, see Maier and Watkins, 2010), are critical for the stressbuffering effects of ketamine (Li et al., 2010; Lepack et al., 2016; for review, see Duman and Krystal, 2016).”
BackgroundMethodInfluentialThe neurophysiology of ketamine: an integrative review
McMillan, R. L., & Muthukumaraswamy, S. D. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0090 · Cited by 56
Shiroma, P. R., Thuras, P., Wels, J., Albott, C. S., Erbes, C., Tye, S., & Lim, K. O. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.08.058 · Cited by 46
Zhang, J., Zhou, H., Yang, J., Jia, J., Niu, L., Sun, Z., Shi, D., Meng, L., Qiu, W., Wang, X., et al. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13463 · Cited by 55
The role of the excitation:inhibition functional balance in the mPFC in the onset of antidepressants
Yin, Y., Wang, Y., Liu, W., Yao, J.-Q., Yuan, J., Li, Z.-H., Ran, Y., Zhang, L., & Li, Y. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108573 · Cited by 54
Khundakar, A. A., & Thomas, A. J. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-148003 · Cited by 53
Glutamate-based depression GBD
McCarthy, D. J., Alexander, R., Smith, M. A., Pathak, S., Kanes, S., Lee, C., & Sanacora, G. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.02.009 · Cited by 55
Niciu, M. J., Grunschel, B. D., Corlett, P. R., Pittenger, C., & Bloch, M. H. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113486718 · Cited by 52
“Moreover, as has been determined from preclinical models of despair (Li et al., 2010, 2011) and a clinical case study (Denk et al., 2011), the molecular cascades set in motion by ketamine persist for at least 24 h post-infusion, for example mammalian target of rapamycin (mTOR) activation, synaptic…”
Targeting Glia Cells: Novel Perspectives for the Treatment of Neuropsychiatric Diseases
Benedetto, B. D., & Rupprecht, R. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311020004 · Cited by 54
“Clinical trials with direct administration of D-serine have indeed already shown a high therapeutic potential to treat SCZ [139], thus paving the way for further studies that focus on D-serine to deeply understand its modes of production, release and regulation in general as a possible candidate to develop or refine t…”
InfluentialGlutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach
Grados, M. A., Specht, M. W., Sung, H.-M., & Fortune, D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.845553 · Cited by 49
“After 24 h, the spine growth translates into stability of spine function [106].”
BackgroundLenze, E. J., Farber, N. B., Kharasch, E., Schweiger, J., Yingling, M., Olney, J., & Newcomer, J. W. (2016) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2016.1142607 · Cited by 50
“Such research would likely require a better understanding of the mechanism of effects of prolonged ketamine infusions on depression-related neurocircuitry (Li et al. 2010), and biosignatures of response (Naughton et al. 2014).”
Impact of rapamycin on status epilepticus induced hippocampal pathology and weight gain
Hester, M. S., Hosford, B. E., Santos, V. R., Singh, S. P., Rolle, I. J., LaSarge, C. L., Liska, J. P., Garcia‐Cairasco, N., & Danzer, S. C. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.03.015 · Cited by 53
“The mTOR pathway is, however, a key regulator of synaptogenesis (Li et al., 2010), synaptic strength (Weston et al., 2014) and long-term potentiation (Stoica et al., 2011).”
BackgroundNeis, V. B., Bettio, L. E. B., Moretti, M., da Rosa, P. B., Ribeiro, C. M., Freitas, A. E., Gonçalves, F. M., Leal, R. B., & Rodrigues, A. L. S. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.10.004 · Cited by 54
Ishikawa, Y., Deyama, S., Shimoda, K., Yoshikawa, K., Ide, S., Satoh, M., & Minami, M. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.06.010 · Cited by 53
Ketamine for the Treatment of Chronic Pain: A Comprehensive Review
Israel, J. E., Pierre, S. S., Ellis, E., Hanukaai, J. S., Noor, N., Varrassi, G., Wells, M., & Kaye, A. D. (2021) · Health Psychology Research · doi:10.52965/001c.25535 · Cited by 54
Johnson, C. R., Kangas, B. D., Jutkiewicz, E. M., Bergman, J., & Coop, A. (2022) · Biomedicines · doi:10.3390/biomedicines10020398 · Cited by 53
Electroconvulsive seizure promotes spine maturation in newborn dentate granule cells in adult rat
Zhao, C., Warner‐Schmidt, J., S. Duman, R., & Gage, F. H. (2012) · Developmental Neurobiology · doi:10.1002/dneu.20986 · Cited by 47
“, 2006), induces new spine formation and spine maturation in medial prefrontal cortex (Li et al., 2010).”
BackgroundResultInfluentialSelf-citationKetamine for a Boost of Neural Plasticity: How, but Also When?
Wu, H., Savalia, N. K., & Kwan, A. C. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.03.014 · Cited by 45
“This framework is supported by several studies showing that a single dose of ketamine increases the number of dendritic spines (1) by elevating their formation rate in the frontal cortex (2,3).”
BackgroundWolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 53
“Animal models have shown that the therapeutic effect of ketamine stems from its ability to promote the growth of dendritic spines, increase the synthesis of synaptic proteins, and strengthen synaptic responses [141, 152, 153].”
BackgroundCui, M., Ji, R., Song, L., Wang, X., Pan, X., Han, Y., Zhai, X., Ai, L., Zhang, W., Xie, A., et al. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.1752-23.2024 · Cited by 52
de Sousa, C. N. S., Meneses, L. N., Vasconcelos, G. S., Silva, M. C. C., da Silva, J. C., Macêdo, D. S., de Lucena, D. F., & Vasconcelos, S. M. M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.08.042 · Cited by 52
“…cortex, one of the most studied brain areas in the biology of depression, is associated with important functions such as problem solving, analysis, control of impulses and motivations, selective attention, emotion control and working memory (Garcia et al., 2009; Li et al., 2010; Cai et al., 2013).”
Chen, K.-T., Tsai, M., Wu, C., Jou, M., Wei, I., & Huang, C. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00162 · Cited by 228
NMDA antagonists under investigation for the treatment of major depressive disorder
Pochwat, B., Pałucha-Poniewiera, A., Szewczyk, B., Pilc, A., & Nowak, G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918951 · Cited by 47
“However, studies of Dybala et al. showed that the antidepressant-like activity of CGP 37849, an NMDARs antagonists in the FST, was not attenuated by NBQX AMPARs antagonist pretreatment [75].”
BackgroundMethodInfluentialZinc deficiency in rats is associated with up-regulation of hippocampal NMDA receptor
Doboszewska, U., Sowa-Kućma, M., Młyniec, K., Pochwat, B., Hołuj, M., Ostachowicz, B., Pilc, A., Nowak, G., & Szewczyk, B. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.09.013 · Cited by 52
Astrocytes in rapid ketamine antidepressant action
Stenovec, M., Li, B., Verkhratsky, A., & Zorec, R. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108158 · Cited by 54
Zhou, Y.-L., Wu, F.-C., Liu, W.-J., Zheng, W., Wang, C.-Y., Zhan, Y.-N., Lan, X.-F., & Ning, Y.-P. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00945-9 · Cited by 49
Elucidating the Possible Role of FoxO in Depression
Rana, T., Behl, T., Sehgal, A., Mehta, V., Singh, S., Sharma, N., & BUNGAU, S. G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03364-4 · Cited by 52
Moosavi, M., Yadollahikhales, G., Rastegar, K., & Zarifkar, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.12.021 · Cited by 52
Pardossi, S., Fagiolini, A., & Cuomo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313098 · Cited by 51
“…synaptic protein synthesis and new dendritic spine formation, processes that are fundamental to the sustained antidepressant effects of ketamine [58,60]. mTORC1 regulates the translation of synaptic proteins, such as synapsin-1 and PSD-95, which are essential for maintaining synaptic stability…”
InfluentialDifferential regulation of GluA1 expression by ketamine and memantine
Zhang, K., Yamaki, V. N., Wei, Z., Zheng, Y., & Cai, X. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.09.002 · Cited by 51
Inflamed brain: Targeting immune changes and inflammation for treatment of depression
Sakamoto, S., Zhu, X., Hasegawa, Y., Karma, S., Obayashi, M., Alway, E., & Kamiya, A. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13286 · Cited by 51
“mTOR signaling is a unique molecular target that can be used to explore drugs with antidepressant action such as ketamine.(74,75) Pentoxifylline, a vasodilator and phosphodiesterase inhibitor, ameliorates inflammation and down-regulates serum levels of TNF-α and CRP.”
BackgroundInvolvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice
Nguyen, L., & Matsumoto, R. R. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.024 · Cited by 51
Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade
Nosyreva, E., Autry, A. E., Kavalali, E. T., & Monteggia, L. M. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00094 · Cited by 51
“ORIGINAL RESEARCH ARTICLE published: 01 December 2014 doi: 10.3389/fnmol.2014.00094 Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade”
BackgroundInfluentialWang, Y., Zhang, N., Liu, L., Jiang, H., Hu, D., Wang, Z., Chen, N., & Zhang, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.024 · Cited by 52
The role of neurotrophic factors in novel, rapid psychiatric treatments
Kim, J., He, M. J., Widmann, A. K., & Lee, F. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01717-x · Cited by 51
“Different rodent studies have hypothesized that the blocking of NMDA receptors on GABAergic interneurons causes disinhibition of spontaneous glutamate release that mediates synaptic plasticity [134 – 136], which may be critical for the rapid and sustained antidepressant effects of ketamine [13, 20].”
BackgroundBechtholt, A. J., Smith, K. L., John, C. S., Kang, H., Carlezon, W. A., Cohen, B. M., & Öngür, D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2169-8 · Cited by 51
“…effects of ketamine in rodents, although three reports using single doses of ketamine suggest antidepressant-like effects lasting 24 h (Sprague–Dawley rats; 10 mg/kg; Li et al. 2010), 10 days (Wistar rats; 160 mg/kg; Yilmaz et al. 2002) or 2 weeks (mice; 2.5 mg/kg; Maeng et al. 2008).”
BackgroundInfluentialQuan, M., Zheng, C., Zhang, N., Han, D., Tian, Y., Zhang, T., & Yang, Z. R. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.03.002 · Cited by 51
Hashimoto, K., & Ishima, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015430 · Cited by 50
Roles of Gasotransmitters in Synaptic Plasticity and Neuropsychiatric Conditions
Shefa, U., Kim, D., Kim, M., Jeong, N. Y., & Jung, J. (2018) · Neural Plasticity · doi:10.1155/2018/1824713 · Cited by 51
“Ketamine is a noncompetitive blocker of NMDAR that also stimulates the mTOR signaling pathway and subsequently increases the synthesis of the proteins involved in synapses to induce fast-acting antidepressant effects [73].”
BackgroundLozupone, M., La Montagna, M., D’Urso, F., Piccininni, C., Sardone, R., Dibello, V., Giannelli, G., Solfrizzi, V., Greco, A., Daniele, A., et al. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1471136 · Cited by 50
“It has recently been demonstrated that the antidepressant effect of ketamine is mediated by activation of the mTOR pathway [37].”
BackgroundKato, T., & Duman, R. S. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172827 · Cited by 49
Self-citationNi, L., Xu, Y., Dong, S., Kong, Y., Wang, H., Lu, G., Wang, Y., Li, Q., Li, C., Du, Z., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0782-1 · Cited by 51
Webhofer, C., Gormanns, P., Tolstikov, V., Zieglgänsberger, W., Sillaber, I., Holsboer, F., & Turck, C. W. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.56 · Cited by 52
“Rapamycin, an inhibitor of mammalian target of rapamycin signaling exhibited antidepressant-like effects in mice and rats,(49) whereas antidepressant effects of ketamine in treatment-resistant depressed patients were attributed to activated mammalian target of rapamycin signaling.(50)”
BackgroundNovel approaches for the management of depressive disorders
Kaster, M. P., Moretti, M., Cunha, M. P., & Rodrigues, A. L. S. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.12.029 · Cited by 52
Smith, G. S. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.1/gsmith · Cited by 36
“More recently, the evidence for a rapid antidepressant action of the N-Methyl-D-aspartate (NMDA) receptor antagonist, ketamine, in treatment-resistant depressed patients had led to preclinical studies that have shown that a single dose of ketamine is associated with increased levels of synaptic proteins and increased…”
Antidepressant drug action--From rapid changes on network function to network rewiring
Rantamäki, T., & Yalcin, I. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.06.001 · Cited by 50
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H., & DeLorenzo, C. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.025 · Cited by 50
“mGluR5 effects are linked to the endoplasmic reticulum via Homer and Shank (see Figure 2), where IP3 causes the release of intracellular calcium stores, producing a variety of downstream effects(90) including activation of mTOR(78).”
Siegel, J. S., Palanca, B. J. A., Ances, B. M., Kharasch, E. D., Schweiger, J. A., Yingling, M. D., Snyder, A. Z., Nicol, G. E., Lenze, E. J., & Farber, N. B. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05762-6 · Cited by 50
“…2 (eEF2), mechanistic target of rapamycin (mTOR), and glycogen synthase kinase-3 (GSK-3), which induces spine formation and synaptogenesis that is necessary and sufficient for antidepressant response (Li et al. 2010; Autry et al. 2011; Liu et al. 2013; Zhou et al. 2014; Moda-Sava et al. 2019).”
BackgroundDonello, J. E., Banerjee, P., Li, Y.-X., Guo, Y.-X., Yoshitake, T., Zhang, X.-L., Miry, O., Kehr, J., Stanton, P. K., Gross, A. L., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy101 · Cited by 50
“Interestingly, despite potentially opposing effects of rapastinel and ketamine on NMDAR activity, the antidepressant-like effects of rapastinel and ketamine both require AMPA receptor (AMPAR) activation and increased mTORC1 signaling (Maeng et al., 2008; Li et al., 2010; Koike et al., 2011; Burgdorf et al., 2013; Zano…”
BackgroundPloski, J. E., & Vaidya, V. A. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.04.009 · Cited by 51
Jiang, C. S., Dileone, R., Pittenger, C., & Duman, R. S. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02796-0 · Cited by 92
“We next determined the effect of naltrexone pretreatment on the ketamine-induced elevation in new synthesis of GluR1 in the mPFC [12, 38].”
BackgroundSelf-citationMolecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
Tuck, J. R., Dunlap, L. E., Khatib, Y. A., Hatzipantelis, C. J., Novak, S. W., Rahn, R. M., Davis, A. R., Mosswood, A., Vernier, A. M. M., Fenton, E. M., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416106122 · Cited by 50
“The dissociative anesthetic ketamine and serotonergic psychedelics are among the best - known psychoplastogens ( 2 – 4 ), though their hallucinogenic effects have limited their clinical use.”
Cunha, M. P., Pazini, F. L., Rosa, J. M., Ramos-Hryb, A. B., Oliveira‐Giacomelli, Á., Kaster, M. P., & Rodrigues, A. L. S. (2015) · Purinergic Signalling · doi:10.1007/s11302-015-9446-7 · Cited by 50
Benedetti, F., Dallaspezia, S., Lorenzi, C., Pirovano, A., Radaelli, D., Locatelli, C., Poletti, S., Colombo, C., & Smeraldi, E. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.039 · Cited by 50
Ketamine-dependent neuronal activation in healthy volunteers
Höflich, A. S., Hahn, A., Küblböck, M., Kranz, G. S., Vanicek, T., Ganger, S., Spies, M., Windischberger, C., Kasper, S. F., Winkler, D., et al. (2016) · Brain Structure and Function · doi:10.1007/s00429-016-1291-0 · Cited by 50
Weckmann, K., Deery, M. J., Howard, J. A., Feret, R., Asara, J. M., Dethloff, F., Filiou, M. D., Labermaier, C., Maccarrone, G., Lilley, K. S., et al. (2019) · Complex Psychiatry · doi:10.1159/000493425 · Cited by 43
Paredes, D., & Morilak, D. A. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00046 · Cited by 50
Luo, H., Wu, P., Cao, Y., Jin, M. J., Shen, T., Wang, J., Huang, J., Han, Q.-Q., He, J., Deng, S., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.005 · Cited by 50
Sakurai, H., Jain, F., Foster, S., Pedrelli, P., Mischoulon, D., Fava, M., & Cusin, C. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.089 · Cited by 45
“We are aware that in pre-clinical studies, there is data considering that ketamine may have a U-shaped antidepressant effect and that higher doses may be less effective for depression-like behaviors in rodents (Chowdhury et al., 2017; Li et al., 2010).”
BackgroundMultistage drug effects of ketamine in the treatment of major depression
Walter, M., Li, S., & Demenescu, L. R. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0535-3 · Cited by 50
“This causes, on one side, an increased synaptogenesis and multiplication of mature dendrite spines [45], and on the other hand, an”
BackgroundMorgan, C. J. A., McAndrew, A., Stevens, T., Nutt, D. J., & Lawn, W. (2016) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.10.009 · Cited by 51
“9 demonstrated to increase synaptic plasticity (53) and synaptogenesis (54) at 24 hours post-infusion in rats.”
BackgroundSuzuki, K., Kim, J.-W., Nosyreva, E., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109918 · Cited by 49
Ho, M.-F., Correia, C., Ingle, J. N., Kaddurah-Daouk, R., Wang, L., Kaufmann, S. H., & Weinshilboum, R. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.032 · Cited by 49
Isoflurane produces antidepressant effects inducing BDNF-TrkB signaling in CUMS mice
Zhang, S.-S., Tian, Y.-H., Jin, S.-J., Wang, W.-C., Zhao, J.-X., Si, X.-M., Zhang, L., Xu, H., & Jin, J.-Y. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05287-z · Cited by 49
“As the representative of rapid antidepressants, ketamine has been shown to promote spine recovery and synaptic regeneration within a very short period of time (Li et al. 2010).”
BackgroundInfluentialGlutamatergic NMDA Receptor as Therapeutic Target for Depression
Réus, G. Z., Abelaira, H. M., Tuon, T., Titus, S. E., Ignácio, Z. M., Rodrigues, A. L. S., & Quevedo, J. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.10.003 · Cited by 50
Xia, B., Chen, C., Zhang, H., Xue, W., Tang, J., Tao, W., Wu, R., Ren, L., Wang, W., & Chen, G. (2016) · Scientific Reports · doi:10.1038/srep35042 · Cited by 49
“Several studies demonstrate that the rapid antidepressant effect of ketamine links to the rapid up-regulation of Akt-mTOR signaling 15,16 .”
Lee, Y., Kim, S. G., Lee, B., Zhang, Y., Kim, Y., Kim, S., Kim, E., Kang, H., & Han, K. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00201 · Cited by 49
“…of a fast-acting antidepressant ketamine is dependent on the activation of mTORC1 pathway that increases the synthesis of excitatory synaptic proteins (such as PSD-95 and glutamate receptors) and the number of dendritic spines in the prefrontal cortex (Li et al., 2010; Abdallah et al., 2015).”
BackgroundSelf-citationZhang, M.-L., Rosenheck, R. A., Lin, X., Li, Q., Zhou, Y., Xiao, Y., Huang, X., Fan, N., & He, H. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.034 · Cited by 49
The possible beneficial effects of creatine for the management of depression
Pazini, F. L., Cunha, M. P., & Rodrigues, A. L. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.08.029 · Cited by 40
“Consequently, BDNF is released from vesicles and tropomyosin-related kinase receptor B (TrkB) receptors are activated, causing the stimulation of several intracellular pathways mediated by kinases such as mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/Akt, which in turn phosphorylates mam…”
Lasič, E., Lisjak, M., Horvat, A., Božić, M., Šakanović, A., Anderluh, G., Verkhratsky, A., Vardjan, N., Jorgačevski, J., Stenovec, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47459-z · Cited by 49
Wei, Y., Tseng, J., Wu, C., Su, F.-C., Weng, W., Hsu, C. H., Chang, K.-H., Wu, C., Hsiao, I., & Lin, C. (2020) · Brain and Behavior · doi:10.1002/brb3.1540 · Cited by 49
“Ketamine acts on NMDAR and results in NMDAR containing GABAergic interneuron hypofunction and subsequent pyramidal neuron hyperexcitability in the frontal cortex (Autry et al., 2011; Li et al., 2010; Nosyreva et al., 2013).”
BackgroundRoles of Akt and ERK in mTOR-Dependent Antidepressant Effects of Vanillic Acid
Chuang, H.-W., Wei, I., Lin, F.-Y., Li, C.-T., Chen, K.-T., Tsai, M., & Huang, C. (2020) · ACS Omega · doi:10.1021/acsomega.9b04271 · Cited by 224
Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
Shin, C., & Kim, Y.-K. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0236 · Cited by 42
Silberbauer, L., Spurny‐Dworak, B., Handschuh, P. A., Klöbl, M., Bednařík, P., Reiter, B., Ritter, V., Trost, P., Konadu, M. E., Windpassinger, M., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.549903 · Cited by 52
“Ketamine administration increases spine formation by activation of the mTOR pathway in rodents (52), a process that is considered to reverse neuronal atrophy associated with depressive pathophysiology (53).”
BackgroundKohtala, S., Alitalo, O., Rosenholm, M., Rozov, S. V., & Rantamäki, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107741 · Cited by 50
Malberg, J. E., Hen, R., & Madsen, T. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.01.010 · Cited by 49
Deyama, S., & Kaneda, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109335 · Cited by 49
Zhou, W., Dong, L., Wang, N., Shi, J.-Y., Yang, J.-J., Zuo, Z.-Y., & Zhou, Z.-Q. (2014) · Neuroimmunomodulation · doi:10.1159/000356517 · Cited by 49
Ketamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors
Zaytseva, A., Bouckova, E., Wiles, M. J., Wustrau, M. H., Schmidt, I. G., Mendez-Vazquez, H., Khatri, L., & Kim, S. (2023) · eLife · doi:10.7554/elife.86022 · Cited by 48
“Although we and others show that GluA1 levels are selectively increased in the hippocampus within one hour after ketamine treatment in mice (Li et al., 2010; Nosyreva et al., 2013; Koike and Chaki, 2014; Yang et al., 2016; Zanos et al., 2016; Georgiou et al., 2022), other groups have also demonstrated an increase in b…”
BackgroundUnderstanding treatment-resistant depression using “omics” techniques: A systematic review
Amasi-Hartoonian, N., Pariante, C. M., Cattaneo, A., & Sforzini, L. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.011 · Cited by 48
Lu, J.-J., Wu, P., He, J., Li, Y.-K., Long, L., Yao, X.-P., Yang, J.-H., Chen, H.-S., Zhang, X., Hu, Z., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02008-z · Cited by 49
Tripathi, A., Bartosh, A., Whitehead, C., & Pillai, A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02189-7 · Cited by 48
“More-over, activation of the mTOR signaling pathway in the PFC plays an important role in the antidepressant action of ketamine [109].”
BackgroundPałucha-Poniewiera, A., Szewczyk, B., & Pilc, A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.001 · Cited by 48
“As was mentioned previously, classic ADs that require several weeks of treatment to elicit therapeutic effects in humans did not induce a rapid activation of the mTOR signaling cascade in the PFC in rats (Li et al., 2010).”
BackgroundInfluentialPodkowa, K., Pochwat, B., Brański, P., Pilc, A., & Pałucha-Poniewiera, A. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4325-7 · Cited by 43
“Interestingly, several studies have shown that functional synaptic changes in the PFC, which appear 24 h after ketamine administration, correlate with the antidepressant effects of the drug in animal models of depression (Koike et al. 2011; Li et al. 2010; Maeng et al. 2008).”
BackgroundMethodResultInfluentialMu, R.-H., Fang, X., Wang, S., Li, C., Chen, S.-M., Chen, X., Liu, Q., Li, Y., & Yi, L. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4357-z · Cited by 48
Nagy, C., Vaillancourt, K., & Turecki, G. (2018) · Genes, Brain and Behavior · doi:10.1111/gbb.12446 · Cited by 44
“through rapid release of BDNF in an activity-dependent manner.(104,125) Furthermore, recent evidence suggests that the therapeutic effects of ketamine may be mediated through epigenetic mechanisms.”
BackgroundMatrine Exerts Antidepressant-Like Effects on Mice: Role of the Hippocampal PI3K/Akt/mTOR Signaling
Wu, Z., You, Z., Chen, P., Chen, C., Chen, F., Shen, J., & Xu, H. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy028 · Cited by 48
“Matrine has been shown to have antiinflammatory, antiallergic, antivirus, antitumor, and cardiovascular protective effects (Li et al., 2010; Fu et al., 2014; Liu et al., 2014; Kan et al., 2015; Wu et al., 2017).”
BackgroundInfluentialdu Jardin, K. G., Liebenberg, N., Cajina, M., Müller, H. K., Elfving, B., Sanchez, C., & Wegener, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00978 · Cited by 47
“In line with previous reports (Garcia et al., 2008; Li et al., 2010; Liebenberg et al., 2015), these data suggest that a single dose of S-ketamine induces an antidepressant-like response within 1 h that is sustained for at least 48 h. 5-HT depletion induced by pCPA pretreatment prevented the acute…”
BackgroundResultLi, Q., Zhang, B., Cao, H., Liu, W., Guo, F., Shen, F., Ye, B., Liu, H., Li, Y., & Liu, Z. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107836 · Cited by 47
Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine
Hashimoto, K. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.176 · Cited by 47
Suzuki, A., Hara, H., & Kimura, H. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109308 · Cited by 46
“, 2014) and activation of mechanistic target of rapamycin (mTOR) via activation of Akt and extracellular signal-regulated kinase (ERK) signaling in the prefrontal cortex (Li et al., 2010).”
BackgroundEvaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder
Markopoulos, A., Inserra, A., De Gregorio, D., & Gobbi, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.749068 · Cited by 46
Rantamäki, T., & Kohtala, S. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018697 · Cited by 45
“The blocking of mTOR by rapamycin also blocks ketamineinduced antidepressant-like effects and accelerated fear extinction responses (Li et al., 2010; Girgenti et al., 2017), suggesting that protein synthesis is important for the consolidation of these effects.”
BackgroundInfluentialDeveloping biomarkers in mood disorders research through the use of rapid-acting antidepressants
Niciu, M. J., Mathews, D. C., Nugent, A. C., Ionescu, D. F., Furey, M. L., Richards, E. M., Machado-Vieira, R., & Zarate, C. A. (2014) · Depression and Anxiety · doi:10.1002/da.22224 · Cited by 45
TrkB neurotrophin receptor at the core of antidepressant effects, but how?
Rantamäki, T. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-02985-6 · Cited by 45
Patton, M. S., Lodge, D. J., Morilak, D. A., & Girotti, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.236 · Cited by 44
“Preclinical studies have also demonstrated rapid antidepressant-like effects of ketamine (Jett et al, 2015; Li et al, 2010; Rogóz et al, 2002).”
BackgroundResultInfluentialRiebe, I., Seth, H., Culley, G., Dósa, Z., Radi, S., Strand, K., Fröjd, V., & Hanse, E. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13128 · Cited by 40
“Ketamine, used as an anaesthetic, has fast anti-depressive actions (Nanxin et al., 2010; Browne & Lucki, 2013), whereas PCP is used to induce schizophrenia-like symptoms in murine animal models (Javitt, 2007; Javitt et al.”
Method
Metadata
- Authors
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S.
- Affiliations
- Yale University (US)
- Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA.
- Corresponding author
- Duman, Ronald S.
- Venue
- Science
- Published
- 2010-08-20
- Volume
- 329
- Issue
- 5994
- Pages
- 959-964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3116441
- OpenAlex
- W2089351762
- Cited by
- 2,881
- References
- 14
- Citations by year
- 2026: 147 · 2025: 161 · 2024: 171 · 2023: 175 · 2022: 218 · 2021: 234 · 2020: 233 · 2019: 202 · 2018: 199 · 2017: 171 · 2016: 205 · 2015: 217 · 2014: 136 · 2013: 153 · 2012: 125
- FWCI
- 96.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute of Mental Health (2P01 MH25642, MH-45481, P01MH025642, R01MH045481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, mTOR signaling, synaptogenesis, NMDA receptor antagonists, rapid antidepressant effects, treatment-resistant depression, prefrontal cortex, dendritic spines, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Neurons, Neuropeptides, Phenols, Piperidines, Synapses, Time Factors, Protein Biosynthesis, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Sirolimus, Intracellular Signaling Peptides and Proteins, Dendritic Spines, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.